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Abstract
Introduction: Products containing anthraquinones (AQ) are mainly used as laxatives and have several biological
effects. Long-term use of AQ laxatives is associated with an increased risk of serious adverse events (AEs), such as
colorectal cancer (CRC). We will systematically synthesize the evidence on the potential association between the
use of AQ laxatives and the risk of CRC.
Methods and analysis: We will search MEDLINE, Embase, Scopus, the Cochrane Library, Google Scholar, and
Clinicaltrials.gov. To avoid missing any relevant studies, we will search the bibliographies of retrieved papers
and recent reviews in the field. Interventions will include products containing oral AQ laxatives, in particular,
those derived from rhubarb, senna, cascara, buckhorn, and aloe. Two review authors will independently screen
title, abstract, and full texts and will independently extract data from included studies. The primary outcome
is the number of participants diagnosed with CRC, while the secondary outcome will be cases of melanosis
coli. We will also consider all other AEs reported in the included studies, in particular, intestinal bleeding,
alterations of gastrointestinal motility, and potential for dependence. When possible and appropriate, for each
outcome, a meta-analysis will be performed.
Discussion: This protocol is prepared in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Protocols guidelines. The protocol gives an insight into the scope and parameters
for the systematic review to be carried out.
Systematic review registration: PROSPERO CRD42019125414
Introduction
Anthraquinones (AQs) are found in rhubarb root, Senna
leaf and pod, Cascara, Buckhorn, and Aloe, and they are
widely used in laxative preparations. AQ laxatives in-
clude physcion, chrysophanol, aloe-emodin, rhein, and
sennosides. After oral ingestion, AQs are generally me-
tabolized to active aglycones, which exert their laxative
effect by damaging epithelial cells, leading directly and
indirectly to changes in intestinal absorption, secretion,
and motility [1]. In particular, two different mechanisms
of action have been proposed: (1) an effect on large in-
testine motility resulting in accelerated colonic transit,
thus reducing fluid absorption, and (2) an effect on se-
cretion processes resulting in enhanced fluid absorption.
At a cellular level, one main target is the inhibition of
the Cl−-channels across colon cells, contributing to the
laxative effect [2]. Moreover, Na+/K+-ATPase pump is
inhibited by those 1,8-dihydroxyanthrones/anthraqui-
nones bearing an additional phenolic hydroxyl group [3].
Damaged epithelial cells can be found in the pigmented
colonic mucosa, a characteristic of melanosis coli, a condi-
tion potentially related to an inappropriate use of AQ laxa-
tives (i.e., more than 2weeks of treatment). The question
whether the melanosis coli predisposes to colorectal cancer
(CRC) is controversial [4], and the relationship between the
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use of AQ laxatives, melanosis coli, and CRC is still
debated.
Pre-clinical studies have shown a potential role of AQ
laxatives in both the initiation and promotion of tumori-
genesis, and studies performed in humans have also sug-
gested tumor promoting activities for these laxatives [5].
CRC is one of the main concerns of modern medicine,
representing one of the most common types of cancer
worldwide [6]. In both sexes, CRC represents the fourth
type of cancer for incidence (6.1% of the total cases) and
the first one for mortality (8.2% of the total cancer deaths).
In high-income countries, AQ laxatives are used by
20% of the population [7]. The World Health
Organization (WHO) has published monographs on
safety, efficacy, and quality control of Aloe, Cassia,
Frangula, and Cascara for their use as medicinal plants
[8]. In the monographs, it is recommended that prod-
ucts containing AQ glycosides should not be used for
longer than 1–2 weeks, due to the possible incidence of
serious AEs, such as electrolyte imbalance. Also the
European Medicines Agency (EMA) recommends not
using AQ laxatives (i.e., those containing rhubarb) for
more than 2 weeks. Otherwise, treatment with product
containing AQ laxatives should always require medical
supervision [9]. In Germany, the Federal Institute for
Medicines and Medical Devices has recommended not
to use AQ laxatives for prolonged periods [10]. Al-
though research to date has shown that long-term use
of AQs does not necessarily lead to serious adverse
events (AEs), it may be prudent to use such products
only for short-term relief of constipation (e.g., potential
for dependence, drug-drug interactions), in particular
when they are used as a self-medication treatment [11].
Recently, the European Food Safety Authority (EFSA)
provided a scientific opinion on the safety of AQ deriva-
tives [12]. EFSA’s document was triggered by concerns
about the possible harmful effects associated with long-
term consumption of AQ-containing preparations (i.e.,
food supplements used as laxatives). In particular, EFSA
reviewed existing scientific evidence on the possible link
between AQ products intake and adverse health effects
(i.e., colorectal cancer) [12]. In their document, the panel
of experts concluded that AQs should be considered as
genotoxic and carcinogenic unless there are specific data
to the contrary. Furthermore, they were unable to pro-
vide safety advice on the daily intake of AQ products.
Since there is no clear evidence of the potential associ-
ation between the use of oral AQ laxatives and the risk
of CRC, we aimed to quantify this risk by performing a
systematic review and meta-analysis.
Methods and analysis
This protocol has been written according to the Preferred
Reporting Items for Systematic review and Meta-Analysis
Protocols guidance [13, 14] and has been registered on
PROSPERO (registration ID CRD42019125414).
Eligibility criteria
Studies will be selected according to the eligibility cri-
teria outlined below.
Study designs
We will consider for inclusion both clinical trials and obser-
vational cohort studies, either prospective or retrospective.
We will also include case-control studies. Observational
cross-sectional studies will be excluded. Similarly, we will
exclude reviews and meta-analyses, letters to the editor,
case reports, case series, and expert opinions.
Participants
We will consider studies performed on subjects taking
AQs as oral laxatives, excluding studies which include
patients with history of any cancer. No restriction on
subjects’ age will be applied.
Interventions
We will consider the following plant-containing AQ
laxatives:
 Senna, syn. Cassia (Cassia acutifolia, C. angustifolia)
 Frangula (Rhamnus frangula)
 Cascara (Rhamnus purshiana, Syn. Cascara sagrada)
 Rhubarb (Rheum officinale, R. palmatum)
 Aloe spp. (Aloe vera, syn. A. barbadensis, A. ferox, A.
arborescens)
We will also consider all active AQ compounds, such
as: physcion, chrysophanol, rhein, dantron, emodin,
aloe-emodin, and senna glycosides (sennoside A and B)
[15]. Additional active compounds or interventions con-
taining AQ laxatives, not listed above and detected by
screening of retrieved references or in the bibliographies
of evaluated studies, will be also considered.
Studies on patients co-treated with more than one
abovementioned AQ laxatives will be included as well.
Comparators
We will consider studies evaluating the effect of the
above mentioned AQ laxatives compared to no treat-
ment and/or compared to non-AQ laxatives.
Outcomes
We will include studies evaluating the primary safety
outcome “CRC” and/or studies evaluating the secondary
safety outcome “melanosis coli”.
In studies evaluating at least one of the abovemen-
tioned safety outcomes, we will also consider the follow-
ing AEs:
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1. Gastrointestinal bleeding
2. Alterations in gastrointestinal motility
3. Potential for dependence
We will also consider any other AEs experienced by
treated subjects in included studies; AEs will be defined
based on authors’ definitions.
Timing
There will be no timing restriction. We will define a
consumption of AQ laxatives less than 2 weeks as
“short-term” use, while “long-term” use will be referred
to as consumption longer than 2 weeks.
Regardless of the time of onset, we will include any
diagnosis of CRC in patients exposed to AQ laxatives for
a period exceeding 2 weeks (“long-term” use). Then we
will perform a stratification based on the latency time,
taking into account the clinical characteristics of each
patient and evaluating the events of CRC on a case-by-
case basis. For this purpose, if necessary, we will request
data at the single patient level from authors of the in-
cluded original studies.
Setting
There will be no restriction by type of setting.
Language
We will include articles written in any language.
Information sources and search strategy
Electronic searches will be performed in the databases
MEDLINE, Embase, Scopus, the Cochrane Library, Goo-
gle Scholar, and Clinicaltrials.gov.
The MEDLINE search strategy is reported below:
1. (anthraquinon*[tiab] OR anthrachinon*[tiab] OR
anthraquinonoid*[tiab] OR carmine*[tiab] OR
cascara*[tiab] OR emodin*[tiab] OR senna*[tiab]
OR cassia*[tiab] OR frangula*[tiab] OR
rhamnus*[tiab] OR rheum[tiab] OR rumex*[tiab]
OR rhubarb*[tiab] OR aloe*[tiab] OR
sennosid*[tiab] OR physcion*[tiab] OR
chrysophanol*[tiab] OR rhein*[tiab] OR
dantron*[tiab] OR laxativ*[tiab] OR propulsiv*[tiab]
OR "anthraquinones"[Mesh] OR "laxatives"[Mesh])
2. (cancer*[tiab] OR carcinom*[tiab] OR neoplas*[tiab]
OR tumor[tiab] OR tumoral[tiab] OR
tumorigen*[tiab] OR malignan*[tiab] OR
oncogen*[tiab] OR mutagen*[tiab] OR oncolog*[tiab]
OR "neoplasms"[Mesh]) AND (intestinal*[tiab] OR
colon*[tiab] OR rectal*[tiab] OR colorectal*[tiab])
3. ("Hyperpigmentation"[Mesh] OR melanosis*[tiab]
OR pigment*[tiab])
4. (case reports[ptyp] OR comment[sb] OR
editorial[ptyp] OR guideline[ptyp] OR meta-
analysis[ptyp] OR practice guideline[ptyp] OR
review[ptyp] OR systematic[sb])
5. (french[lang] OR spanish[lang] OR german[lang] OR
chinese[lang] OR hindi[lang] OR arabic[lang] OR
italian[lang] OR turkish[lang] OR swedish[lang] OR
danish[lang])
6. 2 OR 3
7. 1 AND 6
8. 7 NOT 4 NOT 5
The MEDLINE search strategy will be adapted to the
syntax and subject headings of the Embase, Scopus, the
Cochrane Library, and Google Scholar.
Records will be retrieved on the same day from all
sources.
The search strategy will be updated toward the end of
the review, after being validated to ensure that the MED-
LINE strategy retrieves a high proportion of eligible
studies found through any means and indexed in
MEDLINE.
Study records
Data management
Retrieved records will be managed using the software
EndNote™.
Selection process
Two review authors will independently screen the ex-
tracted records. The two review authors will independ-
ently identify studies for inclusion by screening titles
and abstracts yielded by search, eliminating those
deemed irrelevant. We will retrieve full-text articles for
all references that at least one of the review authors will
identify for potential inclusion.
We will select studies for inclusion on the basis of re-
view of full-text articles. We will resolve discrepancies
through discussion.
Neither of the review authors will be blind to the jour-
nal titles or to the study authors or institutions.
Data collection
Two review authors will independently extract data from
the included studies.
Data abstracted will include demographic information,
methodology, intervention details, all reported clinically
relevant conditions, and outcomes. Data will be ex-
tracted at the trial arm level. We will resolve discrepan-
cies between authors through discussion.
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Data items
Extracted data will include the name of the study au-
thors and year of publication, the study design and char-
acteristics (including single or double blinding and
randomization), the country in which participants were
recruited, and eventual funding sources.
As for the population, we will extract the subjects’ age,
and clinically relevant comorbidities.
As for the intervention and the comparator, we will
extract the active principle of the experimental interven-
tion, its route of administration, the treatment dosage,
and the duration of treatment.
We will extract the number of randomized partici-
pants, the number of participants included in the ana-
lysis, the number of participants with events for binary
outcomes, effect size measurements (i.e., odds ratio
(OR)) and variables entering the multivariable model as
potential confounders, if appropriate. Whenever pos-
sible, we will use results from an intention-to-treat
analysis.
Outcomes and prioritization
The primary safety outcome will be the number of sub-
jects diagnosed with “CRC”, out of the total number of
treated patients.
The secondary safety outcome will be the number of
cases of “melanosis coli”, out of the total number of
treated patients.
For all outcomes, where OR and related confidence in-
tervals (CIs) are reported, these will be transformed to
absolute numbers.
Any AE, if present, will be identified based on specific
authors’ definitions and will be classified using the Med-
DRA classification, according to preferred terms (PT)
and system organ class (SOC) classification [16].
Risk of bias
Two review authors will independently assess the in-
cluded studies for bias. To assess the risk of bias of in-
cluded randomized controlled trials, we will follow the
Cochrane Handbook for Systematic Reviews of Interven-
tions [17]. Specifically, we will assess the risk of bias for
the following domains: selection (random sequence gen-
eration; allocation concealment), performance (blinding
of participants and personnel), detection (blinding of
outcome), attrition (incomplete outcome data), reporting
(selective reporting), and other unclear bias.
To assess the risk of bias of observational studies, we
will follow the Newcastle-Ottawa Quality Assessment
Scale [18]. Specifically, for included cohort studies, we
will consider the following domains: selection (represen-
tativeness of the exposed cohort, selection of the non-
exposed cohort, ascertainment of exposure, absence of
outcome of interest at start of study), comparability, and
outcome (assessment of outcome, appropriate length of
follow-up, adequacy of follow-up of cohorts).
For each domain in the two tools, we will describe the
procedures undertaken for each study, including verba-
tim quotes. A judgment as to the possible risk of bias on
each domain will be made from the extracted informa-
tion, rating from “low-risk” to “high-risk”.
The judgements will be made independently by two
review authors; disagreement will be resolved first by
discussion and then by consulting a third author.
We will compute graphic representations of potential
bias within included studies, using the software RevMan
5.3 (Review Manager 5.3).
Data synthesis
If studies are sufficiently homogeneous in terms of de-
sign and comparator, we will synthesize results using a
meta-analysis [14].
Measures of treatment effect
All considered outcomes are based on dichotomous
data. According to the assessment of statistical hetero-
geneity, if appropriate, for all considered outcomes, we
will perform a meta-analysis using a random-effects
model within a frequentist framework. We will calculate
pooled ORs combining the estimates reported in each
study using random-effects Mantel-Haenszel method.
For all other AEs, no quantitative synthesis will be per-
formed, and the proportions of each reported AE will be
described at study level.
Unit of analysis issues
All analysis will be conducted per trial arm, rather than
at individual patient level.
Dealing with missing data
Study authors will be contacted to obtain the missing
data. If missing data cannot be obtained, the study will
be excluded from the related analysis.
Assessment of heterogeneity
We will evaluate the clinical heterogeneity by consider-
ing the variability in participants’ features among studies
and in study characteristics (study design, intervention,
follow-up).
We will evaluate statistical heterogeneity across studies
using the I-squared and Cochran’s Q tests, and publica-
tion bias using plots of standard error against effect esti-
mate (bias is likely to cause asymmetry in such plots) or
using formal tests such as Egger one or similar.
If high levels of heterogeneity exist (I-squared ≥ 50%
or P < 0.1), we will try to explain the source of hetero-
geneity by conducting subgroup or sensitivity analysis.
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Subgroup and sensitivity analysis
If possible, subgroup analysis will be conducted for dif-
ferent AQ compounds, daily dosages, and duration of
treatment (i.e., short- or long-term use).
Additional subgroup analysis will be performed, if ap-
propriate, according to the clinical characteristics of pa-
tients in included studies.
We will conduct a sensitivity analysis including only
clinical trials versus only observational studies. If pos-
sible, a second sensitivity analysis will be performed in-
cluding only high-quality clinical trials.
Meta-biases
To determine whether reporting bias is present in in-
cluded clinical trials, we will evaluate whether the proto-
col of the clinical trial has been published before
recruitment of study patients. Specifically, for studies
published after July 2005, we will screen the Clinical
Trial Register at ClinicalTrials.gov. We will evaluate
whether selective reporting of outcomes is present (out-
come reporting bias). The potential for reporting bias
will be evaluated using funnel plots (if ≥ 10 studies are
present).
Confidence in cumulative estimate
The quality of evidence will be judged using the
Grading of Recommendations Assessment, Develop-
ment and Evaluation working group (GRADE) scale,
considering the domains of risk of bias, consistency,
directness, precision, and publication bias. Quality
will be adjudicated as high, moderate, low, or very
low [17].
Discussion
To the best of our knowledge, this systematic review and
meta-analysis will provide a comprehensive narrative
synthesis and quantitative estimate of the risk of CRC in
subjects exposed to a long-term treatment with AQ
laxatives.
The pooled estimate will guide clinicians and policy-
makers in informing patients and governments about
the risk associated to the use of products containing AQ
laxatives. This risk could be greater for self-administered
products that are easily available without a medical
prescription.
Moreover, it will provide an estimate of the future glo-
bal CRC burden in the context of the complementary
and alternative medicine. Importantly, this systematic re-
view will enable the identification of clinical, epidemio-
logical, and public health gaps, thus outlining directions
for further investigation.
The findings from the review will be disseminated in a
peer-reviewed journal, and we will recommend or carry
out research to bridge the identified gaps.
Strengths and limitations
A major strength of our study is the comprehensive re-
view within six major databases in order to include all
potential articles. Limitations include the heterogeneity
in the sample size of the retrieved studies and quality of
the study design. Furthermore, prospective studies with
a sufficient follow-up period to observe the occurrence
of CRC may be lacking.
Ethics and dissemination
There is no primary data collection involved in this
study, thus research ethics approval is not required. Re-
sults will be disseminated by release of findings in a
peer-reviewed scientific journal, and by abstracts and
speeches at international meetings and congresses.
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